How Diagnostic Testing for NASH Can Help Identify This Serious and Potentially Fatal Disease, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will explain what is NASH and why is there a need for identifying patients with NASH and liver fibrosis. They will discuss the current tests available for physician’s use and why are they inadequate for diagnosing NASH with liver fibrosis.

Xtalks Life Science Webinars

a test that identifies patients with NASH and significant liver fibrosis is necessary at this time to ensure that patients with NASH are diagnosed and treated effectively, thereby reducing the risk of progressing to NASH related cirrhosis and/or hepatocellular carcinoma.

The prevalence of NAFLD in the United States is reported to be between 10% and 30%, and the pooled overall global prevalence of NAFLD diagnosed by imaging was estimated to be greater than 25%. However, the exact prevalence of NAFLD and NASH in an adult population remains difficult to assess due to the lack of a cost-effective and widely available, minimally-invasive diagnostic test, and to the absence of specific symptoms before end-stages occur. While diet, lifestyle modification and exercise are the current recommendations, there are many promising therapeutics in clinical development for the treatment of NASH that have the potential to provide physicians with new treatment options.

Therefore, a test that identifies patients with NASH and significant liver fibrosis is necessary at this time to ensure that patients with NASH are diagnosed and treated effectively, thereby reducing the risk of progressing to NASH related cirrhosis and/or hepatocellular carcinoma.

Join Charles M. Walworth, MD, Discipline Director, Molecular Infectious Disease, LabCorp/Monogram Biosciences and Arun Sanyal, MD, Professor of Medicine at Virginia Commonwealth University (VCU) School of Medicine, Richmond, VA in a live webinar on Friday, June 26, 2020 at 1pm EDT.

For more information or to register for this event, visit How Diagnostic Testing for NASH Can Help Identify This Serious and Potentially Fatal Disease.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website